Immune Design (IDC) is a biotechnology and healthcare company founded in 2008. Their pioneering technology focuses on developing safe and effective vaccines and therapeutics for the prevention and treatment of infectious diseases. The company's commitment to reducing human suffering is evident in their thorough research on the immune system and the creation of advanced immune-based products for the pharmaceutical sector.
Their last investment, a $50.00M Post-IPO Equity investment on 03 July 2017, signifies confidence in IDC's mission and potential. This investment further reinforces their pursuit of excellence and boundless energy in addressing critical health challenges.
Immune Design Corp. (IDC) is an innovative player in the biotechnology and healthcare industries, leveraging its expertise in the immune system to develop impactful medical solutions. Their focus on creating a significant and positive impact on human health makes them an attractive prospect for venture capital investors seeking to support groundbreaking advancements in healthcare.
